EGFR and non-small cell lung carcinoma: The discovery of epidermal growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKIs), such as gefitinib, significantly improve the clinical efficacy of treatments for patients with EGFR‐mutated advanced NSCLC, improving the patient quality of life and the prognosis.1, 2 However, acquired drug resistance will occur in most patients after a median of 9 to 13 months of treatment.3, 4, 5 The acquired resistance of EGFR‐TKI not only allows the disease to progress in patients but also becomes the bottleneck restricting the continued use of EGFR‐TKI.